SIMILAR PATTERNS OF AMINO ACIDS FOR 3CS9_B_NILB600_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	ALA A 220 GLU A 236 VAL A 239 MET A 240 LEU A 248 THR A 266 GLY A 272	None	0.42A	3cs9B-1k9aA: 28.0	3cs9B-1k9aA: 31.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	ALA A 220 VAL A 239 MET A 240 LEU A 248 THR A 266 GLY A 272 HIS A 312	None	0.50A	3cs9B-1k9aA: 28.0	3cs9B-1k9aA: 31.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	10	ALA A 288 GLU A 305 VAL A 308 MET A 309 ILE A 312 LEU A 317 THR A 334 GLY A 340 HIS A 380 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) None P16 A 2 (-3.3A) None None P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-3.5A)	0.66A	3cs9B-1opkA: 34.3	3cs9B-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 621 GLU A 640 GLY A 676 HIS A 790 ASP A 810 PHE A 811	STI A 3 (-3.5A) STI A 3 (-3.6A) STI A 3 ( 3.8A) STI A 3 (-4.5A) STI A 3 (-3.9A) STI A 3 (-3.6A)	1.01A	3cs9B-1t46A: 32.3	3cs9B-1t46A: 37.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 621 GLU A 640 VAL A 643 THR A 670 GLY A 676 HIS A 790 ASP A 810	STI A 3 (-3.5A) STI A 3 (-3.6A) None STI A 3 (-3.2A) STI A 3 ( 3.8A) STI A 3 (-4.5A) STI A 3 (-3.9A)	0.50A	3cs9B-1t46A: 32.3	3cs9B-1t46A: 37.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA X 37 GLU X 54 MET X 58 LEU X 66 THR X 82 GLY X 88 ALA X 147	STU X 902 (-3.1A) STU X 902 ( 4.4A) None None STU X 902 (-4.1A) STU X 902 (-3.5A) STU X 902 ( 4.1A)	0.55A	3cs9B-2dq7X: 32.0	3cs9B-2dq7X: 45.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA X 37 MET X 58 LEU X 66 THR X 82 GLY X 88 HIS X 128 ALA X 147	STU X 902 (-3.1A) None None STU X 902 (-4.1A) STU X 902 (-3.5A) None STU X 902 ( 4.1A)	0.53A	3cs9B-2dq7X: 32.0	3cs9B-2dq7X: 45.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 184 GLU A 201 VAL A 204 ILE A 208 ALA A 319	None	0.64A	3cs9B-2eu9A: 21.6	3cs9B-2eu9A: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	ALA A 293 LEU A 322 GLY A 344 HIS A 384 ALA A 403	H8H A 534 (-3.2A) None H8H A 534 (-3.3A) None H8H A 534 ( 4.0A)	0.58A	3cs9B-2h8hA: 30.6	3cs9B-2h8hA: 27.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	ALA A 293 LEU A 322 THR A 338 GLY A 344 ALA A 403	H8H A 534 (-3.2A) None H8H A 534 (-3.1A) H8H A 534 (-3.3A) H8H A 534 ( 4.0A)	0.46A	3cs9B-2h8hA: 30.6	3cs9B-2h8hA: 27.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	ALA A 293 LEU A 322 GLY A 344 HIS A 384 ALA A 403	QUE A 1 (-3.5A) None QUE A 1 (-3.0A) None QUE A 1 ( 4.5A)	0.42A	3cs9B-2hckA: 30.5	3cs9B-2hckA: 30.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 271 GLU A 288 VAL A 291 MET A 292 LEU A 300 THR A 316	1BM A 499 (-3.6A) 1BM A 499 (-3.2A) None 1BM A 499 ( 3.8A) None 1BM A 499 (-3.2A)	0.51A	3cs9B-2hk5A: 28.0	3cs9B-2hk5A: 48.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 271 VAL A 291 MET A 292 LEU A 300 THR A 316 GLY A 322 HIS A 362 ALA A 381	1BM A 499 (-3.6A) None 1BM A 499 ( 3.8A) None 1BM A 499 (-3.2A) 1BM A 499 (-3.5A) None 1BM A 499 ( 3.7A)	0.57A	3cs9B-2hk5A: 28.0	3cs9B-2hk5A: 48.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	ALA A 269 GLU A 286 VAL A 289 MET A 290 ILE A 293 LEU A 298 THR A 315 GLY A 321 ALA A 380	GIN A 600 (-3.1A) GIN A 600 (-3.6A) None GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.2A) GIN A 600 (-3.4A) None GIN A 600 (-3.1A)	0.56A	3cs9B-2hz0A: 34.5	3cs9B-2hz0A: 98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLU A 286 MET A 290 LEU A 298 THR A 315 GLY A 321 ALA A 380 ASP A 381	GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-4.2A) GIN A 600 (-3.4A) None GIN A 600 (-3.1A) GIN A 600 (-4.9A)	0.74A	3cs9B-2hz0A: 34.5	3cs9B-2hz0A: 98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 298 THR A 315 GLY A 321 HIS A 361 ALA A 380 ASP A 381	GIN A 600 (-4.2A) GIN A 600 (-3.4A) None GIN A 600 (-4.3A) GIN A 600 (-3.1A) GIN A 600 (-4.9A)	0.71A	3cs9B-2hz0A: 34.5	3cs9B-2hz0A: 98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 289 ILE A 293 LEU A 298 THR A 315 GLY A 321 HIS A 361 ALA A 380	None GIN A 600 (-4.5A) GIN A 600 (-4.2A) GIN A 600 (-3.4A) None GIN A 600 (-4.3A) GIN A 600 (-3.1A)	0.76A	3cs9B-2hz0A: 34.5	3cs9B-2hz0A: 98.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	5	ALA A 452 GLU A 471 MET A 475 GLY A 505 HIS A 544	4ST A1687 (-3.3A) 4ST A1687 ( 4.6A) None 4ST A1687 (-3.2A) None	0.66A	3cs9B-2j0jA: 32.8	3cs9B-2j0jA: 20.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	5	GLU A 471 MET A 475 GLY A 505 HIS A 544 ASP A 564	4ST A1687 ( 4.6A) None 4ST A1687 (-3.2A) None 4ST A1687 (-4.7A)	0.83A	3cs9B-2j0jA: 32.8	3cs9B-2j0jA: 20.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	ALA A 271 GLU A 288 MET A 292 LEU A 300 THR A 316 GLY A 322 HIS A 362 ALA A 381 ASP A 382 PHE A 383	1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.9A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.5A) None 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 4.3A)	0.51A	3cs9B-2og8A: 32.8	3cs9B-2og8A: 47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 614 GLU A 633 MET A 637 THR A 663 GLY A 669 HIS A 776 ASP A 796	None	0.86A	3cs9B-2ogvA: 30.5	3cs9B-2ogvA: 38.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 853 VAL A 875 GLY A 908 HIS A 962 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 ( 4.8A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.45A	3cs9B-2p4iA: 24.3	3cs9B-2p4iA: 37.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 515 GLU A 534 MET A 538 ILE A 541 GLY A 570 ALA A 643	None	0.60A	3cs9B-2psqA: 32.4	3cs9B-2psqA: 35.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 515 MET A 538 ILE A 541 GLY A 570 HIS A 624 ALA A 643	None	0.55A	3cs9B-2psqA: 32.4	3cs9B-2psqA: 35.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 215 GLU A 230 LEU A 244 THR A 265 GLY A 271	ADE A 488 (-3.2A) None None ADE A 488 (-4.3A) ADE A 488 ( 4.1A)	0.62A	3cs9B-2qluA: 25.0	3cs9B-2qluA: 24.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 215 LEU A 244 THR A 265 GLY A 271 HIS A 319 ALA A 338	ADE A 488 (-3.2A) None ADE A 488 (-4.3A) ADE A 488 ( 4.1A) None None	0.62A	3cs9B-2qluA: 25.0	3cs9B-2qluA: 24.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2x4f	MYOSIN LIGHT CHAIN KINASE FAMILY MEMBER 4 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 133 GLU A 151 VAL A 154 MET A 155 LEU A 163	16X A1374 ( 3.8A) None None None None	0.54A	3cs9B-2x4fA: 22.8	3cs9B-2x4fA: 24.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2x4f	MYOSIN LIGHT CHAIN KINASE FAMILY MEMBER 4 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 133 VAL A 154 MET A 155 LEU A 163 HIS A 225	16X A1374 ( 3.8A) None None None None	0.66A	3cs9B-2x4fA: 22.8	3cs9B-2x4fA: 24.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xik	SERINE/THREONINE PROTEIN KINASE 25 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 47 GLU A 66 VAL A 69 GLY A 101 ALA A 157	J60 A1294 (-3.3A) None None J60 A1294 ( 3.8A) J60 A1294 ( 4.2A)	0.64A	3cs9B-2xikA: 19.7	3cs9B-2xikA: 27.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	5	ALA A 651 MET A 674 THR A 699 GLY A 705 HIS A 744	Q9G A1898 (-3.2A) Q9G A1898 (-3.9A) Q9G A1898 (-3.5A) Q9G A1898 ( 3.8A) None	0.48A	3cs9B-2xyuA: 28.5	3cs9B-2xyuA: 38.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	5	ALA A 651 MET A 674 THR A 699 HIS A 744 ASP A 764	Q9G A1898 (-3.2A) Q9G A1898 (-3.9A) Q9G A1898 (-3.5A) None None	0.74A	3cs9B-2xyuA: 28.5	3cs9B-2xyuA: 38.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A1028 VAL A1050 MET A1051 GLY A1082 HIS A1130	S91 A 1 (-3.2A) None None S91 A 1 (-3.3A) None	0.57A	3cs9B-2z8cA: 23.4	3cs9B-2z8cA: 40.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	6	ALA A 273 LEU A 302 THR A 319 GLY A 325 HIS A 365 ALA A 384	None	0.49A	3cs9B-2zv7A: 26.7	3cs9B-2zv7A: 47.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	6	ALA A 273 MET A 294 LEU A 302 THR A 319 HIS A 365 ALA A 384	None	0.79A	3cs9B-2zv7A: 26.7	3cs9B-2zv7A: 47.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 515 MET A 538 ILE A 541 GLY A 570 HIS A 624 ALA A 643	M33 A1996 (-3.3A) None None M33 A1996 ( 4.8A) None None	0.63A	3cs9B-3b2tA: 26.4	3cs9B-3b2tA: 40.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c1x	HEPATOCYTE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A1108 GLY A1163 HIS A1202 ALA A1221 ASP A1222	CKK A1500 (-3.2A) CKK A1500 ( 4.5A) CKK A1500 (-4.2A) CKK A1500 (-3.4A) CKK A1500 (-4.5A)	0.49A	3cs9B-3c1xA: 30.9	3cs9B-3c1xA: 33.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c1x	HEPATOCYTE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLU A1127 GLY A1163 HIS A1202 ALA A1221 ASP A1222	CKK A1500 (-3.4A) CKK A1500 ( 4.5A) CKK A1500 (-4.2A) CKK A1500 (-3.4A) CKK A1500 (-4.5A)	0.66A	3cs9B-3c1xA: 30.9	3cs9B-3c1xA: 33.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 512 GLU A 531 GLY A 567 ALA A 640 PHE A 489	C4F A 1 (-3.3A) None None C4F A 1 (-3.6A) C4F A 1 (-3.7A)	0.82A	3cs9B-3c4fA: 31.8	3cs9B-3c4fA: 40.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 512 GLU A 531 GLY A 567 HIS A 621 ALA A 640	C4F A 1 (-3.3A) None None None C4F A 1 (-3.6A)	0.49A	3cs9B-3c4fA: 31.8	3cs9B-3c4fA: 40.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 512 MET A 535 GLY A 567 HIS A 621 ALA A 640	C4F A 1 (-3.3A) C4F A 1 ( 3.7A) None None C4F A 1 (-3.6A)	0.56A	3cs9B-3c4fA: 31.8	3cs9B-3c4fA: 40.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 220 GLU A 236 VAL A 239 MET A 240 LEU A 248 THR A 266 GLY A 272	None	0.42A	3cs9B-3d7uA: 28.0	3cs9B-3d7uA: 44.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 220 VAL A 239 MET A 240 LEU A 248 THR A 266 GLY A 272 HIS A 312	None	0.49A	3cs9B-3d7uA: 28.0	3cs9B-3d7uA: 44.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	ALA A 663 GLU A 682 MET A 686 HIS A 756 ASP A 776 PHE A 777	IHZ A1001 (-3.3A) IHZ A1001 (-3.8A) IHZ A1001 (-3.5A) IHZ A1001 ( 4.9A) IHZ A1001 (-4.8A) IHZ A1001 (-4.7A)	0.73A	3cs9B-3dkoA: 32.4	3cs9B-3dkoA: 36.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	5	ALA A 663 GLY A 717 HIS A 756 ASP A 776 PHE A 777	IHZ A1001 (-3.3A) IHZ A1001 ( 3.9A) IHZ A1001 ( 4.9A) IHZ A1001 (-4.8A) IHZ A1001 (-4.7A)	0.68A	3cs9B-3dkoA: 32.4	3cs9B-3dkoA: 36.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gp0	MITOGEN-ACTIVATED PROTEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 51 GLU A 71 THR A 106 HIS A 148 ASP A 168	NIL A 1 (-3.7A) NIL A 1 (-3.7A) NIL A 1 (-3.3A) NIL A 1 (-4.3A) NIL A 1 (-4.6A)	0.36A	3cs9B-3gp0A: 22.5	3cs9B-3gp0A: 25.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 859 GLU A 878 GLY A 915 HIS A1020 ASP A1040	8ST A2001 ( 3.8A) 8ST A2001 (-3.7A) None 8ST A2001 ( 4.8A) None	0.75A	3cs9B-3hngA: 31.1	3cs9B-3hngA: 33.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	5	ALA A 80 MET A 104 GLY A 135 HIS A 173 ALA A 192	None	0.68A	3cs9B-3iecA: 22.6	3cs9B-3iecA: 25.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	ALA A 665 GLU A 684 MET A 688 THR A 713 GLY A 719 HIS A 758	None None None None GOL A 403 (-3.4A) None	0.67A	3cs9B-3kulA: 32.4	3cs9B-3kulA: 35.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	5	ALA A 229 THR A 279 GLY A 285 HIS A 330 ALA A 349	LDN A 1 (-3.6A) LDN A 1 (-3.8A) LDN A 1 (-3.3A) None LDN A 1 ( 3.8A)	0.41A	3cs9B-3mdyA: 25.5	3cs9B-3mdyA: 28.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 227 THR A 277 GLY A 283 HIS A 328 ALA A 347	LDN A 600 (-3.2A) LDN A 600 (-4.0A) LDN A 600 (-3.3A) None LDN A 600 ( 3.8A)	0.40A	3cs9B-3my0A: 25.0	3cs9B-3my0A: 28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 109 GLU A 130 VAL A 133 MET A 134 GLY A 165 HIS A 203	JOZ A 361 (-3.4A) SO4 A 5 (-3.1A) None None None None	0.75A	3cs9B-3nuuA: 22.9	3cs9B-3nuuA: 25.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	5	ALA A 576 MET A 600 THR A 625 GLY A 631 HIS A 674	STU A 1 (-3.3A) None STU A 1 (-4.1A) STU A 1 (-3.2A) None	0.37A	3cs9B-3ppzA: 29.0	3cs9B-3ppzA: 35.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	5	GLU A 596 MET A 600 THR A 625 GLY A 631 HIS A 674	None None STU A 1 (-4.1A) STU A 1 (-3.2A) None	0.55A	3cs9B-3ppzA: 29.0	3cs9B-3ppzA: 35.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 217 THR A 267 GLY A 273 HIS A 320 ALA A 339	TAK A 2 (-3.5A) TAK A 2 (-3.5A) TAK A 2 (-3.6A) None TAK A 2 ( 4.2A)	0.52A	3cs9B-3q4tA: 24.2	3cs9B-3q4tA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 217 VAL A 235 THR A 267 GLY A 273 ALA A 339	TAK A 2 (-3.5A) EDO A 489 ( 4.8A) TAK A 2 (-3.5A) TAK A 2 (-3.6A) TAK A 2 ( 4.2A)	0.53A	3cs9B-3q4tA: 24.2	3cs9B-3q4tA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 443 MET A 464 LEU A 472 THR A 489 GLY A 495 HIS A 534	PP2 A 1 (-3.2A) PP2 A 1 ( 4.3A) None PP2 A 1 (-3.3A) PP2 A 1 ( 4.2A) None	0.41A	3cs9B-3sxsA: 31.9	3cs9B-3sxsA: 41.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 512 GLU A 531 MET A 535 GLY A 567 HIS A 621 ALA A 640	07J A 1 (-3.5A) 07J A 1 (-3.8A) 07J A 1 (-3.8A) 07J A 1 (-3.7A) None 07J A 1 (-3.2A)	0.64A	3cs9B-3tt0A: 30.7	3cs9B-3tt0A: 35.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 512 GLU A 531 MET A 535 ILE A 538 GLY A 567 HIS A 621	07J A 1 (-3.5A) 07J A 1 (-3.8A) 07J A 1 (-3.8A) None 07J A 1 (-3.7A) None	0.70A	3cs9B-3tt0A: 30.7	3cs9B-3tt0A: 35.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 570 GLY A 623 HIS A 677 ASP A 697 PHE A 698	0F4 A 902 (-3.2A) 0F4 A 902 (-3.4A) 0F4 A 902 (-4.1A) None 0F4 A 902 (-4.1A)	0.55A	3cs9B-3v5qA: 28.3	3cs9B-3v5qA: 37.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLU A 588 GLY A 623 HIS A 677 ASP A 697 PHE A 698	0F4 A 902 (-3.6A) 0F4 A 902 (-3.4A) 0F4 A 902 (-4.1A) None 0F4 A 902 (-4.1A)	0.62A	3cs9B-3v5qA: 28.3	3cs9B-3v5qA: 37.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 866 GLU A 885 ILE A 892 GLY A 922 HIS A1026 ASP A1046	4TT A2001 (-3.5A) None None 4TT A2001 (-3.7A) None None	0.59A	3cs9B-3vidA: 31.3	3cs9B-3vidA: 34.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 866 GLU A 885 ILE A 892 GLY A 922 HIS A1026	LEV A1201 (-3.5A) LEV A1201 (-3.7A) None LEV A1201 (-3.6A) None	0.59A	3cs9B-3wzdA: 32.7	3cs9B-3wzdA: 38.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 866 GLU A 885 ILE A 892 GLY A 922 HIS A1026	B49 A2000 (-3.5A) None None B49 A2000 ( 3.7A) None	0.68A	3cs9B-4agdA: 31.2	3cs9B-4agdA: 35.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 866 ILE A 892 GLY A 922 HIS A1026 ASP A1046	B49 A2000 (-3.5A) None B49 A2000 ( 3.7A) None None	0.70A	3cs9B-4agdA: 31.2	3cs9B-4agdA: 35.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	5	ALA A 233 THR A 283 GLY A 289 HIS A 334 ALA A 353	TAK A1507 (-3.3A) TAK A1507 (-3.6A) TAK A1507 (-3.5A) None TAK A1507 ( 4.2A)	0.33A	3cs9B-4c02A: 25.2	3cs9B-4c02A: 28.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	ALA A 653 GLU A 672 MET A 676 THR A 701 GLY A 707 HIS A 764 ALA A 783 ASP A 784 PHE A 785	DI1 A1000 (-3.6A) DI1 A1000 (-3.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.6A) None DI1 A1000 (-3.8A) DI1 A1000 (-3.7A) DI1 A1000 (-4.1A) DI1 A1000 (-4.5A)	0.76A	3cs9B-4ckrA: 30.7	3cs9B-4ckrA: 37.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	ALA A 684 GLU A 705 LEU A 720 GLY A 743 ALA A 799	AGS A1985 (-3.5A) None None None AGS A1985 ( 4.5A)	0.70A	3cs9B-4crsA: 17.0	3cs9B-4crsA: 26.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 156 LEU A 189 THR A 205 GLY A 211 HIS A 250	1G0 A 401 (-3.6A) None 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.5A) None	0.61A	3cs9B-4id7A: 24.7	3cs9B-4id7A: 39.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	ALA A 293 LEU A 322 GLY A 344 HIS A 384 ALA A 403	0J9 A 601 (-3.3A) None 0J9 A 601 ( 4.1A) None 0J9 A 601 (-3.5A)	0.36A	3cs9B-4k11A: 30.3	3cs9B-4k11A: 33.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 506 GLU A 525 MET A 529 ILE A 532 GLY A 561 ALA A 634	ACP A 801 (-3.3A) ACP A 801 ( 4.8A) None None ACP A 801 ( 4.6A) None	0.68A	3cs9B-4k33A: 26.8	3cs9B-4k33A: 38.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 506 ILE A 532 GLY A 561 HIS A 615 ALA A 634	ACP A 801 (-3.3A) None ACP A 801 ( 4.6A) None None	0.46A	3cs9B-4k33A: 26.8	3cs9B-4k33A: 38.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	5	ALA A 293 LEU A 322 GLY A 344 HIS A 384 ALA A 403	VGG A 601 (-3.5A) None VGG A 601 ( 3.2A) None VGG A 601 ( 4.2A)	0.30A	3cs9B-4lggA: 30.7	3cs9B-4lggA: 46.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	5	ALA A 293 VAL A 313 LEU A 322 GLY A 344 ALA A 403	VGG A 601 (-3.5A) None None VGG A 601 ( 3.2A) VGG A 601 ( 4.2A)	0.68A	3cs9B-4lggA: 30.7	3cs9B-4lggA: 46.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o27	SERINE/THREONINE-PRO TEIN KINASE 24 (Homo sapiens)	PF00069 (Pkinase)	5	ALA B 51 GLU B 70 GLY B 105 HIS B 142 ALA B 161	ADP B 500 (-3.3A) None None None None	0.72A	3cs9B-4o27B: 19.1	3cs9B-4o27B: 29.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o27	SERINE/THREONINE-PRO TEIN KINASE 24 (Homo sapiens)	PF00069 (Pkinase)	5	ALA B 51 GLU B 70 VAL B 73 GLY B 105 ALA B 161	ADP B 500 (-3.3A) None None None None	0.69A	3cs9B-4o27B: 19.1	3cs9B-4o27B: 29.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	PF00069 (Pkinase)	6	GLU A 94 MET A 98 LEU A 106 THR A 130 HIS A 173 ASP A 193	046 A 401 (-3.7A) 046 A 401 (-3.5A) 046 A 401 ( 4.6A) 046 A 401 (-4.0A) 046 A 401 (-4.1A) 046 A 401 (-4.3A)	0.69A	3cs9B-4o2zA: 21.3	3cs9B-4o2zA: 26.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 67 GLU A 85 MET A 89 THR A 123 GLY A 128 HIS A 171	SIN A 401 ( 3.7A) None None None SIN A 401 (-3.5A) None	0.82A	3cs9B-4o38A: 20.0	3cs9B-4o38A: 25.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 642 GLU A 661 GLY A 697 HIS A 809 ASP A 829 PHE A 830	P30 A1001 (-3.4A) P30 A1001 (-3.6A) P30 A1001 (-3.4A) P30 A1001 ( 4.3A) None P30 A1001 (-3.9A)	0.84A	3cs9B-4rt7A: 27.3	3cs9B-4rt7A: 32.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tpt	LIM DOMAIN KINASE 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 411 HIS A 449 ALA A 468 ASP A 469 PHE A 470	None 35H A 701 ( 4.4A) 35H A 701 (-3.5A) 35H A 701 (-4.7A) 35H A 701 (-4.4A)	0.69A	3cs9B-4tptA: 22.6	3cs9B-4tptA: 28.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	ALA A 35 ILE A 55 THR A 81 GLY A 87 HIS A 127 ALA A 146	ACP A1264 (-2.9A) None ACP A1264 (-4.5A) ACP A1264 (-3.5A) None None	1.45A	3cs9B-4ueuA: 32.8	3cs9B-4ueuA: 65.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	ALA A 35 LEU A 64 THR A 81 GLY A 87 HIS A 127 ALA A 146	ACP A1264 (-2.9A) None ACP A1264 (-4.5A) ACP A1264 (-3.5A) None None	0.42A	3cs9B-4ueuA: 32.8	3cs9B-4ueuA: 65.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 61 GLY A 114 HIS A 153 ALA A 172 ASP A 173	6UI A 700 (-3.3A) 6UI A 700 ( 4.2A) None 6UI A 700 ( 4.1A) None	0.83A	3cs9B-4usfA: 19.7	3cs9B-4usfA: 28.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 501 GLU A 520 MET A 524 GLY A 556 HIS A 610 ALA A 629	40M A1002 ( 4.1A) 40M A1002 (-3.7A) 40M A1002 (-3.8A) 40M A1002 ( 3.7A) None 40M A1002 (-3.0A)	0.54A	3cs9B-4xcuA: 31.4	3cs9B-4xcuA: 39.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 501 GLU A 520 VAL A 523 MET A 524 ILE A 527 GLY A 556 HIS A 610	40M A1002 ( 4.1A) 40M A1002 (-3.7A) None 40M A1002 (-3.8A) None 40M A1002 ( 3.7A) None	0.65A	3cs9B-4xcuA: 31.4	3cs9B-4xcuA: 39.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	8	ALA B 288 VAL B 308 MET B 309 ILE B 312 LEU B 317 GLY B 340 HIS B 380 ALA B 399	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None None 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A)	0.68A	3cs9B-4xeyB: 30.5	3cs9B-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	8	ALA B 288 VAL B 308 MET B 309 LEU B 317 THR B 334 GLY B 340 HIS B 380 ALA B 399	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A)	0.49A	3cs9B-4xeyB: 30.5	3cs9B-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 642 GLU A 661 GLY A 697 HIS A 809 ASP A 829 PHE A 830	P30 A1001 (-3.5A) P30 A1001 (-3.1A) P30 A1001 (-3.5A) P30 A1001 (-4.4A) None P30 A1001 ( 4.1A)	0.79A	3cs9B-4xufA: 31.6	3cs9B-4xufA: 38.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	5	ALA A 428 LEU A 457 THR A 474 GLY A 480 HIS A 519	746 A 702 (-2.4A) None 746 A 702 (-3.7A) 746 A 702 (-3.6A) None	0.50A	3cs9B-4y93A: 30.8	3cs9B-4y93A: 28.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 512 GLU A 531 MET A 535 GLY A 567 HIS A 621 ALA A 640	38O A1769 (-3.6A) EDO A1766 (-4.1A) EDO A1766 (-3.5A) 38O A1769 (-3.4A) None EDO A1766 ( 4.4A)	0.51A	3cs9B-5a46A: 30.9	3cs9B-5a46A: 38.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 512 GLU A 531 MET A 535 ILE A 538 HIS A 621	38O A1769 (-3.6A) EDO A1766 (-4.1A) EDO A1766 (-3.5A) None None	0.72A	3cs9B-5a46A: 30.9	3cs9B-5a46A: 38.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 625 GLU A 644 MET A 648 THR A 674 GLY A 680 HIS A 816 ASP A 836	748 A1001 (-3.7A) 748 A1001 (-3.3A) 748 A1001 (-3.4A) 748 A1001 (-3.2A) 748 A1001 ( 4.0A) 748 A1001 (-3.8A) 748 A1001 (-4.8A)	0.61A	3cs9B-5grnA: 27.5	3cs9B-5grnA: 36.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 43 GLU A 61 MET A 65 GLY A 96 ALA A 153	6G2 A 901 (-3.2A) None None 6G2 A 901 (-3.6A) 6G2 A 901 ( 4.2A)	0.67A	3cs9B-5j5tA: 22.0	3cs9B-5j5tA: 24.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 43 MET A 65 GLY A 96 HIS A 134 ALA A 153	6G2 A 901 (-3.2A) None 6G2 A 901 (-3.6A) None 6G2 A 901 ( 4.2A)	0.60A	3cs9B-5j5tA: 22.0	3cs9B-5j5tA: 24.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 743 GLU A 762 VAL A 765 MET A 766 HIS A 835	6HJ A1101 (-3.1A) 6HJ A1101 ( 4.2A) None 6HJ A1101 ( 4.1A) None	0.67A	3cs9B-5j9zA: 31.0	3cs9B-5j9zA: 37.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 297 GLU A 315 VAL A 318 MET A 319 GLY A 350	IPW A 601 (-3.5A) IPW A 601 (-3.9A) None IPW A 601 (-4.1A) IPW A 601 ( 3.8A)	0.58A	3cs9B-5kbrA: 22.3	3cs9B-5kbrA: 24.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 297 VAL A 318 MET A 319 GLY A 350 HIS A 387	IPW A 601 (-3.5A) None IPW A 601 (-4.1A) IPW A 601 ( 3.8A) None	0.84A	3cs9B-5kbrA: 22.3	3cs9B-5kbrA: 24.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5l6o	EPHRIN TYPE-B RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 663 MET A 686 THR A 711 HIS A 756 ASP A 776	6P6 A1001 (-3.3A) 6P6 A1001 ( 4.2A) 6P6 A1001 (-3.5A) DIO A1002 (-4.1A) None	0.55A	3cs9B-5l6oA: 31.8	3cs9B-5l6oA: 37.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 617 MET A 641 GLY A 677 HIS A 721 ALA A 740	7AE A1000 (-3.3A) None 7AE A1000 ( 3.7A) None 7AE A1000 ( 3.7A)	0.60A	3cs9B-5td2A: 30.3	3cs9B-5td2A: 42.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cnh	SERINE/THREONINE-PRO TEIN KINASE PRP4 HOMOLOG (Homo sapiens)	no annotation	5	ALA A 715 GLU A 732 HIS A 813 ASP A 834 PHE A 835	919 A1101 (-3.5A) 919 A1101 (-3.7A) 919 A1101 (-4.2A) 919 A1101 (-4.5A) 919 A1101 ( 4.1A)	0.58A	3cs9B-6cnhA: 21.9	3cs9B-6cnhA: 16.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	5	ALA A 217 THR A 264 GLY A 270 HIS A 310 ASP A 330	FKY A9001 (-3.3A) FKY A9001 (-3.0A) FKY A9001 (-3.3A) FKY A9001 (-3.9A) None	0.68A	3cs9B-6cz4A: 22.5	3cs9B-6cz4A: 18.18

[["3CS9_B_NILB600_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"ALA A 220;GLU A 236;VAL A 239;MET A 240;LEU A 248;THR A 266;GLY A 272","None","0.42A","3cs9B-1k9aA:28.0","3cs9B-1k9aA:31.07"],["3CS9_B_NILB600_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"ALA A 220;VAL A 239;MET A 240;LEU A 248;THR A 266;GLY A 272;HIS A 312","None","0.50A","3cs9B-1k9aA:28.0","3cs9B-1k9aA:31.07"],["3CS9_B_NILB600_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",10,"ALA A 288;GLU A 305;VAL A 308;MET A 309;ILE A 312;LEU A 317;THR A 334;GLY A 340;HIS A 380;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;P16 A   2 (-3.3A);None;None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-3.5A)","0.66A","3cs9B-1opkA:34.3","3cs9B-1opkA:57.29"],["3CS9_B_NILB600_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",6,"ALA A 621;GLU A 640;GLY A 676;HIS A 790;ASP A 810;PHE A 811","STI A   3 (-3.5A);STI A   3 (-3.6A);STI A   3 ( 3.8A);STI A   3 (-4.5A);STI A   3 (-3.9A);STI A   3 (-3.6A)","1.01A","3cs9B-1t46A:32.3","3cs9B-1t46A:37.06"],["3CS9_B_NILB600_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",7,"ALA A 621;GLU A 640;VAL A 643;THR A 670;GLY A 676;HIS A 790;ASP A 810","STI A   3 (-3.5A);STI A   3 (-3.6A);None;STI A   3 (-3.2A);STI A   3 ( 3.8A);STI A   3 (-4.5A);STI A   3 (-3.9A)","0.50A","3cs9B-1t46A:32.3","3cs9B-1t46A:37.06"],["3CS9_B_NILB600_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"ALA X  37;GLU X  54;MET X  58;LEU X  66;THR X  82;GLY X  88;ALA X 147","STU X 902 (-3.1A);STU X 902 ( 4.4A);None;None;STU X 902 (-4.1A);STU X 902 (-3.5A);STU X 902 ( 4.1A)","0.55A","3cs9B-2dq7X:32.0","3cs9B-2dq7X:45.45"],["3CS9_B_NILB600_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"ALA X  37;MET X  58;LEU X  66;THR X  82;GLY X  88;HIS X 128;ALA X 147","STU X 902 (-3.1A);None;None;STU X 902 (-4.1A);STU X 902 (-3.5A);None;STU X 902 ( 4.1A)","0.53A","3cs9B-2dq7X:32.0","3cs9B-2dq7X:45.45"],["3CS9_B_NILB600_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",5,"ALA A 184;GLU A 201;VAL A 204;ILE A 208;ALA A 319","None","0.64A","3cs9B-2eu9A:21.6","3cs9B-2eu9A:24.24"],["3CS9_B_NILB600_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"ALA A 293;LEU A 322;GLY A 344;HIS A 384;ALA A 403","H8H A 534 (-3.2A);None;H8H A 534 (-3.3A);None;H8H A 534 ( 4.0A)","0.58A","3cs9B-2h8hA:30.6","3cs9B-2h8hA:27.93"],["3CS9_B_NILB600_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"ALA A 293;LEU A 322;THR A 338;GLY A 344;ALA A 403","H8H A 534 (-3.2A);None;H8H A 534 (-3.1A);H8H A 534 (-3.3A);H8H A 534 ( 4.0A)","0.46A","3cs9B-2h8hA:30.6","3cs9B-2h8hA:27.93"],["3CS9_B_NILB600_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"ALA A 293;LEU A 322;GLY A 344;HIS A 384;ALA A 403","QUE A   1 (-3.5A);None;QUE A   1 (-3.0A);None;QUE A   1 ( 4.5A)","0.42A","3cs9B-2hckA:30.5","3cs9B-2hckA:30.67"],["3CS9_B_NILB600_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",6,"ALA A 271;GLU A 288;VAL A 291;MET A 292;LEU A 300;THR A 316","1BM A 499 (-3.6A);1BM A 499 (-3.2A);None;1BM A 499 ( 3.8A);None;1BM A 499 (-3.2A)","0.51A","3cs9B-2hk5A:28.0","3cs9B-2hk5A:48.00"],["3CS9_B_NILB600_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",8,"ALA A 271;VAL A 291;MET A 292;LEU A 300;THR A 316;GLY A 322;HIS A 362;ALA A 381","1BM A 499 (-3.6A);None;1BM A 499 ( 3.8A);None;1BM A 499 (-3.2A);1BM A 499 (-3.5A);None;1BM A 499 ( 3.7A)","0.57A","3cs9B-2hk5A:28.0","3cs9B-2hk5A:48.00"],["3CS9_B_NILB600_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",9,"ALA A 269;GLU A 286;VAL A 289;MET A 290;ILE A 293;LEU A 298;THR A 315;GLY A 321;ALA A 380","GIN A 600 (-3.1A);GIN A 600 (-3.6A);None;GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.2A);GIN A 600 (-3.4A);None;GIN A 600 (-3.1A)","0.56A","3cs9B-2hz0A:34.5","3cs9B-2hz0A:98.18"],["3CS9_B_NILB600_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",7,"GLU A 286;MET A 290;LEU A 298;THR A 315;GLY A 321;ALA A 380;ASP A 381","GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-4.2A);GIN A 600 (-3.4A);None;GIN A 600 (-3.1A);GIN A 600 (-4.9A)","0.74A","3cs9B-2hz0A:34.5","3cs9B-2hz0A:98.18"],["3CS9_B_NILB600_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"LEU A 298;THR A 315;GLY A 321;HIS A 361;ALA A 380;ASP A 381","GIN A 600 (-4.2A);GIN A 600 (-3.4A);None;GIN A 600 (-4.3A);GIN A 600 (-3.1A);GIN A 600 (-4.9A)","0.71A","3cs9B-2hz0A:34.5","3cs9B-2hz0A:98.18"],["3CS9_B_NILB600_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",7,"VAL A 289;ILE A 293;LEU A 298;THR A 315;GLY A 321;HIS A 361;ALA A 380","None;GIN A 600 (-4.5A);GIN A 600 (-4.2A);GIN A 600 (-3.4A);None;GIN A 600 (-4.3A);GIN A 600 (-3.1A)","0.76A","3cs9B-2hz0A:34.5","3cs9B-2hz0A:98.18"],["3CS9_B_NILB600_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",5,"ALA A 452;GLU A 471;MET A 475;GLY A 505;HIS A 544","4ST A1687 (-3.3A);4ST A1687 ( 4.6A);None;4ST A1687 (-3.2A);None","0.66A","3cs9B-2j0jA:32.8","3cs9B-2j0jA:20.00"],["3CS9_B_NILB600_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",5,"GLU A 471;MET A 475;GLY A 505;HIS A 544;ASP A 564","4ST A1687 ( 4.6A);None;4ST A1687 (-3.2A);None;4ST A1687 (-4.7A)","0.83A","3cs9B-2j0jA:32.8","3cs9B-2j0jA:20.00"],["3CS9_B_NILB600_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",10,"ALA A 271;GLU A 288;MET A 292;LEU A 300;THR A 316;GLY A 322;HIS A 362;ALA A 381;ASP A 382;PHE A 383","1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.9A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.5A);None;1N8 A 501 ( 3.3A);1N8 A 501 ( 3.3A);1N8 A 501 ( 4.3A)","0.51A","3cs9B-2og8A:32.8","3cs9B-2og8A:47.97"],["3CS9_B_NILB600_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"ALA A 614;GLU A 633;MET A 637;THR A 663;GLY A 669;HIS A 776;ASP A 796","None","0.86A","3cs9B-2ogvA:30.5","3cs9B-2ogvA:38.89"],["3CS9_B_NILB600_1","2p4i","Homo sapiens","ANGIOPOIETIN-1 RECEPTOR","PF07714(Pkinase_Tyr)",7,"ALA A 853;VAL A 875;GLY A 908;HIS A 962;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 ( 4.8A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.45A","3cs9B-2p4iA:24.3","3cs9B-2p4iA:37.30"],["3CS9_B_NILB600_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"ALA A 515;GLU A 534;MET A 538;ILE A 541;GLY A 570;ALA A 643","None","0.60A","3cs9B-2psqA:32.4","3cs9B-2psqA:35.50"],["3CS9_B_NILB600_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"ALA A 515;MET A 538;ILE A 541;GLY A 570;HIS A 624;ALA A 643","None","0.55A","3cs9B-2psqA:32.4","3cs9B-2psqA:35.50"],["3CS9_B_NILB600_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",5,"ALA A 215;GLU A 230;LEU A 244;THR A 265;GLY A 271","ADE A 488 (-3.2A);None;None;ADE A 488 (-4.3A);ADE A 488 ( 4.1A)","0.62A","3cs9B-2qluA:25.0","3cs9B-2qluA:24.69"],["3CS9_B_NILB600_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"ALA A 215;LEU A 244;THR A 265;GLY A 271;HIS A 319;ALA A 338","ADE A 488 (-3.2A);None;ADE A 488 (-4.3A);ADE A 488 ( 4.1A);None;None","0.62A","3cs9B-2qluA:25.0","3cs9B-2qluA:24.69"],["3CS9_B_NILB600_1","2x4f","Homo sapiens","MYOSIN LIGHT CHAIN KINASE FAMILY MEMBER 4","PF00069(Pkinase)",5,"ALA A 133;GLU A 151;VAL A 154;MET A 155;LEU A 163","16X A1374 ( 3.8A);None;None;None;None","0.54A","3cs9B-2x4fA:22.8","3cs9B-2x4fA:24.03"],["3CS9_B_NILB600_1","2x4f","Homo sapiens","MYOSIN LIGHT CHAIN KINASE FAMILY MEMBER 4","PF00069(Pkinase)",5,"ALA A 133;VAL A 154;MET A 155;LEU A 163;HIS A 225","16X A1374 ( 3.8A);None;None;None;None","0.66A","3cs9B-2x4fA:22.8","3cs9B-2x4fA:24.03"],["3CS9_B_NILB600_1","2xik","Homo sapiens","SERINE\/THREONINE PROTEIN KINASE 25","PF00069(Pkinase)",5,"ALA A  47;GLU A  66;VAL A  69;GLY A 101;ALA A 157","J60 A1294 (-3.3A);None;None;J60 A1294 ( 3.8A);J60 A1294 ( 4.2A)","0.64A","3cs9B-2xikA:19.7","3cs9B-2xikA:27.67"],["3CS9_B_NILB600_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",5,"ALA A 651;MET A 674;THR A 699;GLY A 705;HIS A 744","Q9G A1898 (-3.2A);Q9G A1898 (-3.9A);Q9G A1898 (-3.5A);Q9G A1898 ( 3.8A);None","0.48A","3cs9B-2xyuA:28.5","3cs9B-2xyuA:38.31"],["3CS9_B_NILB600_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",5,"ALA A 651;MET A 674;THR A 699;HIS A 744;ASP A 764","Q9G A1898 (-3.2A);Q9G A1898 (-3.9A);Q9G A1898 (-3.5A);None;None","0.74A","3cs9B-2xyuA:28.5","3cs9B-2xyuA:38.31"],["3CS9_B_NILB600_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",5,"ALA A1028;VAL A1050;MET A1051;GLY A1082;HIS A1130","S91 A   1 (-3.2A);None;None;S91 A   1 (-3.3A);None","0.57A","3cs9B-2z8cA:23.4","3cs9B-2z8cA:40.52"],["3CS9_B_NILB600_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",6,"ALA A 273;LEU A 302;THR A 319;GLY A 325;HIS A 365;ALA A 384","None","0.49A","3cs9B-2zv7A:26.7","3cs9B-2zv7A:47.18"],["3CS9_B_NILB600_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",6,"ALA A 273;MET A 294;LEU A 302;THR A 319;HIS A 365;ALA A 384","None","0.79A","3cs9B-2zv7A:26.7","3cs9B-2zv7A:47.18"],["3CS9_B_NILB600_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"ALA A 515;MET A 538;ILE A 541;GLY A 570;HIS A 624;ALA A 643","M33 A1996 (-3.3A);None;None;M33 A1996 ( 4.8A);None;None","0.63A","3cs9B-3b2tA:26.4","3cs9B-3b2tA:40.45"],["3CS9_B_NILB600_1","3c1x","Homo sapiens","HEPATOCYTE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"ALA A1108;GLY A1163;HIS A1202;ALA A1221;ASP A1222","CKK A1500 (-3.2A);CKK A1500 ( 4.5A);CKK A1500 (-4.2A);CKK A1500 (-3.4A);CKK A1500 (-4.5A)","0.49A","3cs9B-3c1xA:30.9","3cs9B-3c1xA:33.79"],["3CS9_B_NILB600_1","3c1x","Homo sapiens","HEPATOCYTE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"GLU A1127;GLY A1163;HIS A1202;ALA A1221;ASP A1222","CKK A1500 (-3.4A);CKK A1500 ( 4.5A);CKK A1500 (-4.2A);CKK A1500 (-3.4A);CKK A1500 (-4.5A)","0.66A","3cs9B-3c1xA:30.9","3cs9B-3c1xA:33.79"],["3CS9_B_NILB600_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"ALA A 512;GLU A 531;GLY A 567;ALA A 640;PHE A 489","C4F A   1 (-3.3A);None;None;C4F A   1 (-3.6A);C4F A   1 (-3.7A)","0.82A","3cs9B-3c4fA:31.8","3cs9B-3c4fA:40.45"],["3CS9_B_NILB600_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"ALA A 512;GLU A 531;GLY A 567;HIS A 621;ALA A 640","C4F A   1 (-3.3A);None;None;None;C4F A   1 (-3.6A)","0.49A","3cs9B-3c4fA:31.8","3cs9B-3c4fA:40.45"],["3CS9_B_NILB600_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"ALA A 512;MET A 535;GLY A 567;HIS A 621;ALA A 640","C4F A   1 (-3.3A);C4F A   1 ( 3.7A);None;None;C4F A   1 (-3.6A)","0.56A","3cs9B-3c4fA:31.8","3cs9B-3c4fA:40.45"],["3CS9_B_NILB600_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"ALA A 220;GLU A 236;VAL A 239;MET A 240;LEU A 248;THR A 266;GLY A 272","None","0.42A","3cs9B-3d7uA:28.0","3cs9B-3d7uA:44.10"],["3CS9_B_NILB600_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"ALA A 220;VAL A 239;MET A 240;LEU A 248;THR A 266;GLY A 272;HIS A 312","None","0.49A","3cs9B-3d7uA:28.0","3cs9B-3d7uA:44.10"],["3CS9_B_NILB600_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"ALA A 663;GLU A 682;MET A 686;HIS A 756;ASP A 776;PHE A 777","IHZ A1001 (-3.3A);IHZ A1001 (-3.8A);IHZ A1001 (-3.5A);IHZ A1001 ( 4.9A);IHZ A1001 (-4.8A);IHZ A1001 (-4.7A)","0.73A","3cs9B-3dkoA:32.4","3cs9B-3dkoA:36.77"],["3CS9_B_NILB600_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",5,"ALA A 663;GLY A 717;HIS A 756;ASP A 776;PHE A 777","IHZ A1001 (-3.3A);IHZ A1001 ( 3.9A);IHZ A1001 ( 4.9A);IHZ A1001 (-4.8A);IHZ A1001 (-4.7A)","0.68A","3cs9B-3dkoA:32.4","3cs9B-3dkoA:36.77"],["3CS9_B_NILB600_1","3gp0","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 11","PF00069(Pkinase)",5,"ALA A  51;GLU A  71;THR A 106;HIS A 148;ASP A 168","NIL A   1 (-3.7A);NIL A   1 (-3.7A);NIL A   1 (-3.3A);NIL A   1 (-4.3A);NIL A   1 (-4.6A)","0.36A","3cs9B-3gp0A:22.5","3cs9B-3gp0A:25.76"],["3CS9_B_NILB600_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"ALA A 859;GLU A 878;GLY A 915;HIS A1020;ASP A1040","8ST A2001 ( 3.8A);8ST A2001 (-3.7A);None;8ST A2001 ( 4.8A);None","0.75A","3cs9B-3hngA:31.1","3cs9B-3hngA:33.97"],["3CS9_B_NILB600_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",5,"ALA A  80;MET A 104;GLY A 135;HIS A 173;ALA A 192","None","0.68A","3cs9B-3iecA:22.6","3cs9B-3iecA:25.93"],["3CS9_B_NILB600_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"ALA A 665;GLU A 684;MET A 688;THR A 713;GLY A 719;HIS A 758","None;None;None;None;GOL A 403 (-3.4A);None","0.67A","3cs9B-3kulA:32.4","3cs9B-3kulA:35.31"],["3CS9_B_NILB600_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",5,"ALA A 229;THR A 279;GLY A 285;HIS A 330;ALA A 349","LDN A   1 (-3.6A);LDN A   1 (-3.8A);LDN A   1 (-3.3A);None;LDN A   1 ( 3.8A)","0.41A","3cs9B-3mdyA:25.5","3cs9B-3mdyA:28.36"],["3CS9_B_NILB600_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",5,"ALA A 227;THR A 277;GLY A 283;HIS A 328;ALA A 347","LDN A 600 (-3.2A);LDN A 600 (-4.0A);LDN A 600 (-3.3A);None;LDN A 600 ( 3.8A)","0.40A","3cs9B-3my0A:25.0","3cs9B-3my0A:28.12"],["3CS9_B_NILB600_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"ALA A 109;GLU A 130;VAL A 133;MET A 134;GLY A 165;HIS A 203","JOZ A 361 (-3.4A);SO4 A   5 (-3.1A);None;None;None;None","0.75A","3cs9B-3nuuA:22.9","3cs9B-3nuuA:25.93"],["3CS9_B_NILB600_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",5,"ALA A 576;MET A 600;THR A 625;GLY A 631;HIS A 674","STU A   1 (-3.3A);None;STU A   1 (-4.1A);STU A   1 (-3.2A);None","0.37A","3cs9B-3ppzA:29.0","3cs9B-3ppzA:35.86"],["3CS9_B_NILB600_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",5,"GLU A 596;MET A 600;THR A 625;GLY A 631;HIS A 674","None;None;STU A   1 (-4.1A);STU A   1 (-3.2A);None","0.55A","3cs9B-3ppzA:29.0","3cs9B-3ppzA:35.86"],["3CS9_B_NILB600_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",5,"ALA A 217;THR A 267;GLY A 273;HIS A 320;ALA A 339","TAK A   2 (-3.5A);TAK A   2 (-3.5A);TAK A   2 (-3.6A);None;TAK A   2 ( 4.2A)","0.52A","3cs9B-3q4tA:24.2","3cs9B-3q4tA:25.00"],["3CS9_B_NILB600_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",5,"ALA A 217;VAL A 235;THR A 267;GLY A 273;ALA A 339","TAK A   2 (-3.5A);EDO A 489 ( 4.8A);TAK A   2 (-3.5A);TAK A   2 (-3.6A);TAK A   2 ( 4.2A)","0.53A","3cs9B-3q4tA:24.2","3cs9B-3q4tA:25.00"],["3CS9_B_NILB600_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",6,"ALA A 443;MET A 464;LEU A 472;THR A 489;GLY A 495;HIS A 534","PP2 A   1 (-3.2A);PP2 A   1 ( 4.3A);None;PP2 A   1 (-3.3A);PP2 A   1 ( 4.2A);None","0.41A","3cs9B-3sxsA:31.9","3cs9B-3sxsA:41.16"],["3CS9_B_NILB600_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ALA A 512;GLU A 531;MET A 535;GLY A 567;HIS A 621;ALA A 640","07J A   1 (-3.5A);07J A   1 (-3.8A);07J A   1 (-3.8A);07J A   1 (-3.7A);None;07J A   1 (-3.2A)","0.64A","3cs9B-3tt0A:30.7","3cs9B-3tt0A:35.73"],["3CS9_B_NILB600_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ALA A 512;GLU A 531;MET A 535;ILE A 538;GLY A 567;HIS A 621","07J A   1 (-3.5A);07J A   1 (-3.8A);07J A   1 (-3.8A);None;07J A   1 (-3.7A);None","0.70A","3cs9B-3tt0A:30.7","3cs9B-3tt0A:35.73"],["3CS9_B_NILB600_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"ALA A 570;GLY A 623;HIS A 677;ASP A 697;PHE A 698","0F4 A 902 (-3.2A);0F4 A 902 (-3.4A);0F4 A 902 (-4.1A);None;0F4 A 902 (-4.1A)","0.55A","3cs9B-3v5qA:28.3","3cs9B-3v5qA:37.46"],["3CS9_B_NILB600_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"GLU A 588;GLY A 623;HIS A 677;ASP A 697;PHE A 698","0F4 A 902 (-3.6A);0F4 A 902 (-3.4A);0F4 A 902 (-4.1A);None;0F4 A 902 (-4.1A)","0.62A","3cs9B-3v5qA:28.3","3cs9B-3v5qA:37.46"],["3CS9_B_NILB600_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"ALA A 866;GLU A 885;ILE A 892;GLY A 922;HIS A1026;ASP A1046","4TT A2001 (-3.5A);None;None;4TT A2001 (-3.7A);None;None","0.59A","3cs9B-3vidA:31.3","3cs9B-3vidA:34.44"],["3CS9_B_NILB600_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",5,"ALA A 866;GLU A 885;ILE A 892;GLY A 922;HIS A1026","LEV A1201 (-3.5A);LEV A1201 (-3.7A);None;LEV A1201 (-3.6A);None","0.59A","3cs9B-3wzdA:32.7","3cs9B-3wzdA:38.29"],["3CS9_B_NILB600_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",5,"ALA A 866;GLU A 885;ILE A 892;GLY A 922;HIS A1026","B49 A2000 (-3.5A);None;None;B49 A2000 ( 3.7A);None","0.68A","3cs9B-4agdA:31.2","3cs9B-4agdA:35.28"],["3CS9_B_NILB600_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",5,"ALA A 866;ILE A 892;GLY A 922;HIS A1026;ASP A1046","B49 A2000 (-3.5A);None;B49 A2000 ( 3.7A);None;None","0.70A","3cs9B-4agdA:31.2","3cs9B-4agdA:35.28"],["3CS9_B_NILB600_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",5,"ALA A 233;THR A 283;GLY A 289;HIS A 334;ALA A 353","TAK A1507 (-3.3A);TAK A1507 (-3.6A);TAK A1507 (-3.5A);None;TAK A1507 ( 4.2A)","0.33A","3cs9B-4c02A:25.2","3cs9B-4c02A:28.27"],["3CS9_B_NILB600_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",9,"ALA A 653;GLU A 672;MET A 676;THR A 701;GLY A 707;HIS A 764;ALA A 783;ASP A 784;PHE A 785","DI1 A1000 (-3.6A);DI1 A1000 (-3.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.6A);None;DI1 A1000 (-3.8A);DI1 A1000 (-3.7A);DI1 A1000 (-4.1A);DI1 A1000 (-4.5A)","0.76A","3cs9B-4ckrA:30.7","3cs9B-4ckrA:37.58"],["3CS9_B_NILB600_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",5,"ALA A 684;GLU A 705;LEU A 720;GLY A 743;ALA A 799","AGS A1985 (-3.5A);None;None;None;AGS A1985 ( 4.5A)","0.70A","3cs9B-4crsA:17.0","3cs9B-4crsA:26.30"],["3CS9_B_NILB600_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",5,"ALA A 156;LEU A 189;THR A 205;GLY A 211;HIS A 250","1G0 A 401 (-3.6A);None;1G0 A 401 (-3.2A);1G0 A 401 ( 4.5A);None","0.61A","3cs9B-4id7A:24.7","3cs9B-4id7A:39.65"],["3CS9_B_NILB600_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"ALA A 293;LEU A 322;GLY A 344;HIS A 384;ALA A 403","0J9 A 601 (-3.3A);None;0J9 A 601 ( 4.1A);None;0J9 A 601 (-3.5A)","0.36A","3cs9B-4k11A:30.3","3cs9B-4k11A:33.03"],["3CS9_B_NILB600_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",6,"ALA A 506;GLU A 525;MET A 529;ILE A 532;GLY A 561;ALA A 634","ACP A 801 (-3.3A);ACP A 801 ( 4.8A);None;None;ACP A 801 ( 4.6A);None","0.68A","3cs9B-4k33A:26.8","3cs9B-4k33A:38.23"],["3CS9_B_NILB600_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",5,"ALA A 506;ILE A 532;GLY A 561;HIS A 615;ALA A 634","ACP A 801 (-3.3A);None;ACP A 801 ( 4.6A);None;None","0.46A","3cs9B-4k33A:26.8","3cs9B-4k33A:38.23"],["3CS9_B_NILB600_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",5,"ALA A 293;LEU A 322;GLY A 344;HIS A 384;ALA A 403","VGG A 601 (-3.5A);None;VGG A 601 ( 3.2A);None;VGG A 601 ( 4.2A)","0.30A","3cs9B-4lggA:30.7","3cs9B-4lggA:46.34"],["3CS9_B_NILB600_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",5,"ALA A 293;VAL A 313;LEU A 322;GLY A 344;ALA A 403","VGG A 601 (-3.5A);None;None;VGG A 601 ( 3.2A);VGG A 601 ( 4.2A)","0.68A","3cs9B-4lggA:30.7","3cs9B-4lggA:46.34"],["3CS9_B_NILB600_1","4o27","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 24","PF00069(Pkinase)",5,"ALA B  51;GLU B  70;GLY B 105;HIS B 142;ALA B 161","ADP B 500 (-3.3A);None;None;None;None","0.72A","3cs9B-4o27B:19.1","3cs9B-4o27B:29.31"],["3CS9_B_NILB600_1","4o27","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 24","PF00069(Pkinase)",5,"ALA B  51;GLU B  70;VAL B  73;GLY B 105;ALA B 161","ADP B 500 (-3.3A);None;None;None;None","0.69A","3cs9B-4o27B:19.1","3cs9B-4o27B:29.31"],["3CS9_B_NILB600_1","4o2z","Leishmania donovani","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","PF00069(Pkinase)",6,"GLU A  94;MET A  98;LEU A 106;THR A 130;HIS A 173;ASP A 193","046 A 401 (-3.7A);046 A 401 (-3.5A);046 A 401 ( 4.6A);046 A 401 (-4.0A);046 A 401 (-4.1A);046 A 401 (-4.3A)","0.69A","3cs9B-4o2zA:21.3","3cs9B-4o2zA:26.21"],["3CS9_B_NILB600_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",6,"ALA A  67;GLU A  85;MET A  89;THR A 123;GLY A 128;HIS A 171","SIN A 401 ( 3.7A);None;None;None;SIN A 401 (-3.5A);None","0.82A","3cs9B-4o38A:20.0","3cs9B-4o38A:25.53"],["3CS9_B_NILB600_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"ALA A 642;GLU A 661;GLY A 697;HIS A 809;ASP A 829;PHE A 830","P30 A1001 (-3.4A);P30 A1001 (-3.6A);P30 A1001 (-3.4A);P30 A1001 ( 4.3A);None;P30 A1001 (-3.9A)","0.84A","3cs9B-4rt7A:27.3","3cs9B-4rt7A:32.03"],["3CS9_B_NILB600_1","4tpt","Homo sapiens","LIM DOMAIN KINASE 2","PF07714(Pkinase_Tyr)",5,"GLY A 411;HIS A 449;ALA A 468;ASP A 469;PHE A 470","None;35H A 701 ( 4.4A);35H A 701 (-3.5A);35H A 701 (-4.7A);35H A 701 (-4.4A)","0.69A","3cs9B-4tptA:22.6","3cs9B-4tptA:28.12"],["3CS9_B_NILB600_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"ALA A  35;ILE A  55;THR A  81;GLY A  87;HIS A 127;ALA A 146","ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);ACP A1264 (-3.5A);None;None","1.45A","3cs9B-4ueuA:32.8","3cs9B-4ueuA:65.83"],["3CS9_B_NILB600_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"ALA A  35;LEU A  64;THR A  81;GLY A  87;HIS A 127;ALA A 146","ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);ACP A1264 (-3.5A);None;None","0.42A","3cs9B-4ueuA:32.8","3cs9B-4ueuA:65.83"],["3CS9_B_NILB600_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",5,"ALA A  61;GLY A 114;HIS A 153;ALA A 172;ASP A 173","6UI A 700 (-3.3A);6UI A 700 ( 4.2A);None;6UI A 700 ( 4.1A);None","0.83A","3cs9B-4usfA:19.7","3cs9B-4usfA:28.22"],["3CS9_B_NILB600_1","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"ALA A 501;GLU A 520;MET A 524;GLY A 556;HIS A 610;ALA A 629","40M A1002 ( 4.1A);40M A1002 (-3.7A);40M A1002 (-3.8A);40M A1002 ( 3.7A);None;40M A1002 (-3.0A)","0.54A","3cs9B-4xcuA:31.4","3cs9B-4xcuA:39.67"],["3CS9_B_NILB600_1","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",7,"ALA A 501;GLU A 520;VAL A 523;MET A 524;ILE A 527;GLY A 556;HIS A 610","40M A1002 ( 4.1A);40M A1002 (-3.7A);None;40M A1002 (-3.8A);None;40M A1002 ( 3.7A);None","0.65A","3cs9B-4xcuA:31.4","3cs9B-4xcuA:39.67"],["3CS9_B_NILB600_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",8,"ALA B 288;VAL B 308;MET B 309;ILE B 312;LEU B 317;GLY B 340;HIS B 380;ALA B 399","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;None;1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A)","0.68A","3cs9B-4xeyB:30.5","3cs9B-4xeyB:74.39"],["3CS9_B_NILB600_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",8,"ALA B 288;VAL B 308;MET B 309;LEU B 317;THR B 334;GLY B 340;HIS B 380;ALA B 399","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A)","0.49A","3cs9B-4xeyB:30.5","3cs9B-4xeyB:74.39"],["3CS9_B_NILB600_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"ALA A 642;GLU A 661;GLY A 697;HIS A 809;ASP A 829;PHE A 830","P30 A1001 (-3.5A);P30 A1001 (-3.1A);P30 A1001 (-3.5A);P30 A1001 (-4.4A);None;P30 A1001 ( 4.1A)","0.79A","3cs9B-4xufA:31.6","3cs9B-4xufA:38.59"],["3CS9_B_NILB600_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",5,"ALA A 428;LEU A 457;THR A 474;GLY A 480;HIS A 519","746 A 702 (-2.4A);None;746 A 702 (-3.7A);746 A 702 (-3.6A);None","0.50A","3cs9B-4y93A:30.8","3cs9B-4y93A:28.57"],["3CS9_B_NILB600_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",6,"ALA A 512;GLU A 531;MET A 535;GLY A 567;HIS A 621;ALA A 640","38O A1769 (-3.6A);EDO A1766 (-4.1A);EDO A1766 (-3.5A);38O A1769 (-3.4A);None;EDO A1766 ( 4.4A)","0.51A","3cs9B-5a46A:30.9","3cs9B-5a46A:38.62"],["3CS9_B_NILB600_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",5,"ALA A 512;GLU A 531;MET A 535;ILE A 538;HIS A 621","38O A1769 (-3.6A);EDO A1766 (-4.1A);EDO A1766 (-3.5A);None;None","0.72A","3cs9B-5a46A:30.9","3cs9B-5a46A:38.62"],["3CS9_B_NILB600_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",7,"ALA A 625;GLU A 644;MET A 648;THR A 674;GLY A 680;HIS A 816;ASP A 836","748 A1001 (-3.7A);748 A1001 (-3.3A);748 A1001 (-3.4A);748 A1001 (-3.2A);748 A1001 ( 4.0A);748 A1001 (-3.8A);748 A1001 (-4.8A)","0.61A","3cs9B-5grnA:27.5","3cs9B-5grnA:36.39"],["3CS9_B_NILB600_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",5,"ALA A  43;GLU A  61;MET A  65;GLY A  96;ALA A 153","6G2 A 901 (-3.2A);None;None;6G2 A 901 (-3.6A);6G2 A 901 ( 4.2A)","0.67A","3cs9B-5j5tA:22.0","3cs9B-5j5tA:24.13"],["3CS9_B_NILB600_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",5,"ALA A  43;MET A  65;GLY A  96;HIS A 134;ALA A 153","6G2 A 901 (-3.2A);None;6G2 A 901 (-3.6A);None;6G2 A 901 ( 4.2A)","0.60A","3cs9B-5j5tA:22.0","3cs9B-5j5tA:24.13"],["3CS9_B_NILB600_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"ALA A 743;GLU A 762;VAL A 765;MET A 766;HIS A 835","6HJ A1101 (-3.1A);6HJ A1101 ( 4.2A);None;6HJ A1101 ( 4.1A);None","0.67A","3cs9B-5j9zA:31.0","3cs9B-5j9zA:37.21"],["3CS9_B_NILB600_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",5,"ALA A 297;GLU A 315;VAL A 318;MET A 319;GLY A 350","IPW A 601 (-3.5A);IPW A 601 (-3.9A);None;IPW A 601 (-4.1A);IPW A 601 ( 3.8A)","0.58A","3cs9B-5kbrA:22.3","3cs9B-5kbrA:24.30"],["3CS9_B_NILB600_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",5,"ALA A 297;VAL A 318;MET A 319;GLY A 350;HIS A 387","IPW A 601 (-3.5A);None;IPW A 601 (-4.1A);IPW A 601 ( 3.8A);None","0.84A","3cs9B-5kbrA:22.3","3cs9B-5kbrA:24.30"],["3CS9_B_NILB600_1","5l6o","Homo sapiens","EPHRIN TYPE-B RECEPTOR 3","PF07714(Pkinase_Tyr)",5,"ALA A 663;MET A 686;THR A 711;HIS A 756;ASP A 776","6P6 A1001 (-3.3A);6P6 A1001 ( 4.2A);6P6 A1001 (-3.5A);DIO A1002 (-4.1A);None","0.55A","3cs9B-5l6oA:31.8","3cs9B-5l6oA:37.79"],["3CS9_B_NILB600_1","5td2","Homo sapiens","TYROSINE-PROTEIN KINASE MER","PF07714(Pkinase_Tyr)",5,"ALA A 617;MET A 641;GLY A 677;HIS A 721;ALA A 740","7AE A1000 (-3.3A);None;7AE A1000 ( 3.7A);None;7AE A1000 ( 3.7A)","0.60A","3cs9B-5td2A:30.3","3cs9B-5td2A:42.66"],["3CS9_B_NILB600_1","6cnh","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PRP4 HOMOLOG","no annotation",5,"ALA A 715;GLU A 732;HIS A 813;ASP A 834;PHE A 835","919 A1101 (-3.5A);919 A1101 (-3.7A);919 A1101 (-4.2A);919 A1101 (-4.5A);919 A1101 ( 4.1A)","0.58A","3cs9B-6cnhA:21.9","3cs9B-6cnhA:16.31"],["3CS9_B_NILB600_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",5,"ALA A 217;THR A 264;GLY A 270;HIS A 310;ASP A 330","FKY A9001 (-3.3A);FKY A9001 (-3.0A);FKY A9001 (-3.3A);FKY A9001 (-3.9A);None","0.68A","3cs9B-6cz4A:22.5","3cs9B-6cz4A:18.18"]]